# US 2022/0088159 A1 · Novel immunotherapeutic molecules and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088159 A1
- Document ID: US20220088159A1
- Status: Published application
- Kind: A1
- Application number: 17/374,519
- Filed: 2021-07-13
- Published: 2022-03-24
- Earliest claimed: 2012-10-30
- Assignees: Aravax Pty Ltd
- Applicants: Aravax Pty Ltd
- Inventors: Robyn O'Hehir; Jennifer Rolland; Sara Prickett
- Web page: https://patentgrep.com/patent/US20220088159A1

## CPC

- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/35: Allergens
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method for reducing the severity of Ara h 1 hypersensitivity or sensitivity in a subject to an allergen present in a composition which comprises Ara h 1, said method comprising administering to said subject an effective amount of a composition comprising one or more peptides, wherein said one or more peptides is no more than 28 amino acids in length and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-10, 12-17, and 19-33,
thereby reducing the severity of Ara h 1 hypersensitivity or sensitivity to an allergen present the composition which comprises Ara h 1 in the subject.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The method according to claim 35, wherein said condition is hypersensitivity to peanuts or tree nuts which contain Ara h 1.

### Claim 38

(canceled)

### Claim 39 (depends on 35)

The method according to claim 35, wherein said method desensitises or induces immunological tolerance to Ara h 1.

### Claim 40 (depends on 39)

The method according to claim 39 wherein said desensitization or tolerance is achieved by inducing Th2 anergy or apoptosis.

### Claim 41 (depends on 35)

The method according to claim 35, wherein the composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.

### Claim at position 9

-44. (canceled)

### Claim 45 (depends on 35)

The method according to claim 35, wherein said peptides are capable of modifying T cell function when presented to T cells isolated from subjects having an Ara h 1 hypersensitivity or sensitivity to an allergen present in a composition which comprises Ara h 1.

### Claim 46 (depends on 35)

The method according to claim 35, wherein at least one peptide consists of VEIKEGALMLPHFNSKA (SEQ ID NO: 23).

### Claim 47 (depends on 35)

The method according to claim 35, wherein said peptides are selected from the list:
(i)
(SEQ ID NO: 12)
FQNLQNHRIV
(ii)
(SEQ ID NO: 13)
RIVQIEAKPNTLV
(iii)
(SEQ ID NO: 14)
FQNLQNHRIVQIEAKPNTLV
(iv)
(SEQ ID NO: 15)
WSTRSSENNEGVIVKVSKE
(v)
(SEQ ID NO: 16)
STRSSENNEGVIVKVSKE
(vi)
(SEQ ID NO: 17)
ENNEGVIVKVSKE
(vii)
(SEQ ID NO: 19)
SNNFGKLFEVKPDKKNPQ
(viii)
(SEQ ID NO: 20)
EVKPDKKNPQLQ
(ix)
(SEQ ID NO: 21)
NNFGKLFEVKPDKKNPQLQ
(x)
(SEQ ID NO: 22)
SNNFGKLFEVKPDKKNPQLQ
(xi)
(SEQ ID NO: 24)
ALMLPHFNSKAMVIVVV
(xii)
(SEQ ID NO: 25)
KAMVIVVVNKG
(xiii)
(SEQ ID NO: 26)
AMVIVVVNKGTGNLELVAV
(xiv)
(SEQ ID NO: 27)
VVNKGTGNLELVAVRK
(xv)
(SEQ ID NO: 28)
AMVIVVVNKGTGNLELV
(xvi)
(SEQ ID NO: 29)
KAMVIVVVNKGTGNLELVAV
(xvii)
(SEQ ID NO: 30)
GDVFIMPAAHPVAINASS
(xviii)
(SEQ ID NO: 31)
VFIMPAAHPVAINASSE
(xix)
(SEQ ID NO: 32)
GDVFIMPAAHPVAINASSE
(xx)
(SEQ ID NO: 33)
VFIMPAAHPVAINASS.

### Claim 48 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 23 together with one or more of the peptides defined by SEQ ID NOs: 12-22 or 24-33.

### Claim 49 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 23 together with one or more of the peptides defined by SEQ ID NOs: 14, 16, 20, or 33.

### Claim 50 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 23 together with one or more of the peptides defined by SEQ ID NOs: 14, 20, or 33.

### Claim 51 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 23 together with the peptides defined by SEQ ID NOs: 14, 20, and 33.

### Claim 52 (depends on 35)

The method according to claim 35, wherein at least one peptide consists of
(SEQ ID NO: 14)
FQNLQNHRIVQIEAKPNTLV.

### Claim 53 (depends on 35)

The method according to claim 35, wherein at least one peptide consists of
(SEQ ID NO: 20)
EVKPDKKNPQLQ.

### Claim 54 (depends on 35)

The method according to claim 35, wherein at least one peptide consists of
(SEQ ID NO: 33)
VFIMPAAHPVAINASS.

### Claim 55 (depends on 47)

The method of claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 14 together with one or more of the peptides defined by SEQ ID NOs: 12-13 or 15-33.

### Claim 56 (depends on 47)

The method of claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 20 together with one or more of the peptides defined by SEQ ID NOs: 12-19 or 21-33.

### Claim 57 (depends on 47)

The method of claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 33 together with one or more of the peptides defined by SEQ ID NOs: 12-32.

### Claim 58 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 14 together with one or more of the peptides defined by SEQ ID NOs: 16, 20, 23, or 33.

### Claim 59 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 20 together with one or more of the peptides defined by SEQ ID NOs: 14, 16, 23, or 33.

### Claim 60 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 33 together with one or more of the peptides defined by SEQ ID NOs: 14, 16, 20, or 23.

### Claim 61 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 14 together with one or more of the peptides defined by SEQ ID NOs: 20, 23, or 33.

### Claim 62 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 20 together with one or more of the peptides defined by SEQ ID NOs: 14, 23, or 33.

### Claim 63 (depends on 47)

The method according to claim 47, wherein said composition comprises the peptide defined by SEQ ID NO: 33 together with one or more of the peptides defined by SEQ ID NOs: 14, 20, or 23.
